Clinical Trial

FT819 in Subjects With B-cell Malignancies

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-11-10; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2024-07-31
Status change: Not Yet Recruiting → Recruiting 2021-08-30
Trial Details
NCT Number NCT04629729
Lead Sponsor Fate Therapeutics
Conditions Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
Enrollment 54 participants
Start Date 2021-07-12
Primary Completion 2025-06-18 (estimated)
Study Completion 2039-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-19